Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $104.3 million.

  • Krystal Biotech's Net Cash Flow rose 46600.48% to $104.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $151.2 million, marking a year-over-year increase of 126226.84%. This contributed to the annual value of $151.2 million for FY2025, which is 126226.84% up from last year.
  • Latest data reveals that Krystal Biotech reported Net Cash Flow of $104.3 million as of Q4 2025, which was up 46600.48% from $39.1 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Net Cash Flow registered a high of $135.1 million during Q2 2023, and its lowest value of -$72.6 million during Q2 2021.
  • In the last 5 years, Krystal Biotech's Net Cash Flow had a median value of -$13.8 million in 2023 and averaged $11.4 million.
  • Within the past 5 years, the most significant YoY rise in Krystal Biotech's Net Cash Flow was 46600.48% (2025), while the steepest drop was 748615.07% (2025).
  • Krystal Biotech's Net Cash Flow (Quarter) stood at $54.6 million in 2021, then tumbled by 144.79% to -$24.5 million in 2022, then soared by 39.62% to -$14.8 million in 2023, then tumbled by 92.97% to -$28.5 million in 2024, then soared by 466.0% to $104.3 million in 2025.
  • Its last three reported values are $104.3 million in Q4 2025, $39.1 million for Q3 2025, and $44.0 million during Q2 2025.